De-escalation in low-risk, HER2-positive breast cancer

Lancet Oncol. 2023 Mar;24(3):200-201. doi: 10.1016/S1470-2045(23)00064-5.

Authors

Elena Geuna¹, Giuseppe Curigliano², Filippo Montemurro³

Affiliations

¹ Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
² Division of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Breast Unit, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy. Electronic address: filippo.montemurro@ircc.it.

PMID: 36858719
DOI: 10.1016/S1470-2045(23)00064-5

No abstract available

Publication types

Comment

MeSH terms

Breast Neoplasms*
Female
Humans
Risk